Antibody-Coupled T Cell Receptor
ACTR, or Antibody-Coupled T Cell Receptor, was initially discovered by Dr. Dario Campana, one of the early pioneers in CAR T-cell therapy. Unum has turned Dario’s discovery into a therapeutic platform, making it possible to use a cancer patient’s genetically engineered T cells to attack their cancer. ACTR is unique because it connects the cancer cell-killing ability of T cells with the tumor-targeting ability of co-administered antibodies. ACTR therapies are designed to be highly selective, persistent, and controllable.
ACTRs are engineered from immune cell receptor components to direct and amplify T cell response:
The CD16 extracellular domain of a natural killer (NK) Fc receptor (the receptor normally expressed on natural killer cells allowing them to recognize antibodies) allows ACTR T cells to detect and engage tumor-targeting antibodies, homing in on cancer cells.
Once engaged, the receptor and antibody work to stimulate T cell activation, stimulating tumor cell killing while promoting T cell survival and persistence against cancer cells.